Epkinly (epcoritamab-bysp) is approved to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after 2 or more lines of systemic therapy.
Polivy plus R-CHP is approved for the first-line treatment of patients with DLBCL NOS or HGBL who have an IPI score of 2 or greater.
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
An FDA panel voted in favor of approving polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL.
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
Rapcabtagene autoleucel may elicit durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
Tisagenlecleucel plus pembrolizumab produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
